Total
0
Shares
Resverlogix - CEO, Donald McCaffrey.
CEO, Donald McCaffrey.
Source: Resverlogix.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Resverlogix (RVX) is in discussions to launch Phase 2 COVID-19 clinical studies with Apabetalone in Morocco
  • The company’s upcoming Phase 2 trials in Canada and Brazil will involve a total of 100 subjects
  • A Phase 3 COVID-19 trial in the U.S. will begin in the coming months
  • Studies demonstrate that Apabetalone has the potential to act against COVID-19 by preventing the virus from entering cells and averting runaway inflammatory reactions
  • Resverlogix is a late-stage biotechnology company developing epigenetic therapies for the benefit of patients with chronic disease
  • Resverlogix (RVX) is up by 12.07 per cent and is currently trading at $0.65 per share

Resverlogix (RVX) is in discussions to launch Phase 2 COVID-19 clinical studies with Apabetalone in Morocco.

Donald J. McCaffrey, President and CEO of Resverlogix, stated,

“We are pleased to collaborate with the Kingdom of Morocco’s Ministry of Health under the leadership of Professor Bouchra Meddah, Director of Medicines and Pharmacy, for the possible launch of COVID-19 clinical studies with our novel epigenetic drug, Apabetalone. It is imperative to clear hospital beds of COVID-19 patients to allow urgent surgeries and other necessities to take place, which will contribute to reopening and strengthening the economy in the Kingdom of Morocco.”

Professor Bouchra Meddah, Director of Medicines and Pharmacy, Ministry of Health, Kingdom of Morocco, added,

“The Kingdom of Morocco’s Ministry of Health is pleased to be collaborating with Resverlogix on this important global initiative that has tragically impacted so many people worldwide. Our team was very impressed by the publications from Cell Journal, Nature Report, along with Health Canada and FDA approvals for COVID-19 clinical trials. Our Ministry has also recognized the FDA’s granting to Resverlogix of the coveted Breakthrough Therapy Designation for Apabetalone in a cardiovascular indication.”

Resverlogix’s upcoming Phase 2 trials in Canada and Brazil will involve a total of 100 subjects. Each will receive twice-daily doses of Apabetalone for up to four weeks alongside standard of care, compared to standard of care alone. The primary outcome measure for the study will be a change in the World Health Organization’s Ordinal Scale for Clinical Improvement.

Additionally, a Phase 3 COVID-19 trial in the U.S. will begin in the coming months.

Apabetalone (RVX-208) is an epigenetic small molecule that prevents disease by turning genes on and off through the regulation of gene expression.

Studies demonstrate that the molecule has the potential to act against COVID-19 by preventing the virus from entering cells and replicating, as well as averting runaway inflammatory reactions that can cause severe and lasting organ damage.

In February 2020, Apabetalone became the first therapy of its kind to receive the Breakthrough Therapy Designation by the U.S. FDA to potentially prevent major adverse cardiac events in high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Resverlogix is a late-stage biotechnology company developing epigenetic therapies for the benefit of patients with chronic diseases.

Resverlogix (RVX) is up by 12.07 per cent and is currently trading at $0.65 per share as of 12:20 pm ET.

More From The Market Herald
Theratechnologies - CEO, Paul Lévesque.

" Theratechnologies (TSX:TH) receives 2021 ADRIQ Innovation Award

Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category.

" Elixxer Ltd. (TSXV:ELXR) welcomes new director

Elixxer (ELXR) is pleased to welcome Mr. Jeremy Green to the corporation’s board of directors. 

" Psyence Group (CSE:PSYG) to speak at the annual Global Wellness Summit

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.

" Leveljump Healthcare Corp. (TSXV:JUMP) announces investment in Real Time Medical

Leveljump Healthcare (JUMP) has agreed to acquire a 14.6 per cent equity interest in Real Time Medical.